|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Anti-TNF alpha in the treatment of ulcerative colitis:A valid approach for organ-sparing or an expensive option to delay surgery?显示文摘Ulcerative colitis(UC)is an inflammatory bowel disease affecting large bowel with variable clinical course.The history of disease has been modified by the introduction of biologic therapy,in particular Infliximab(IFX),that has demonstrated efficacy in inducing fast symptoms remission,promoting mucosal healing and maintaining long-term remission.However,surgery is still needed for UC patients:in case of failure of medical therapy and if acute complications or a malignancy occurred.Surgical treatment is associated with a short-term postoperative mortality and morbidity respectively of 0%-4%and 30%.In this study we systematically analyzed:the role of IFX in reducing the colectomy rate,the risk of post-operative morbidity in pre-operatively IFX-treated patients and the cost-effectiveness of IFX therapy.Four of 5 analyzed randomized controlled trials demonstrated that therapy with IFX significantly reduces the colectomy rate.Moreover,pre-operative treatment with IFX doesn’t seem to increase post-operative infectious complications.By an economic point of view,the cost-effectiveness of IFX-therapy was demonstrated for UC patients suffering from moderate to severe UC in a study based on a cost estimation of the National Health Service of England and Wales.However,the argument is debated. | Gianluca Rizzo Daniela Pugliese Alessandro Armuzzi Claudio Coco | 2014 | World Journal of Gastroenterology2014，20，17： | 5 |
| 2 | Management of perianal fistulas in Crohn's disease:An upto-date review显示文摘Perianal disease is one of the most disabling manifestations of Crohn's disease.A multidisciplinary approach of gastroenterologist,colorectal surgeon and radiologist is necessary for its management.A correct diagnosis,based on endoscopy,magnetic resonance imaging,endoanal ultrasound and examination under anesthesia,is crucial for perianal fistula treatment.Available medical and surgical therapies are discussedin this review,including new local treatment modalities that are under investigation. | Manuela Marzo Carla Felice Daniela Pugliese Gianluca Andrisani Giammarco Mocci Alessandro Armuzzi Luisa Guidi | 2015 | World Journal of Gastroenterology2015，21，5： | 5 |
| 3 | Effect of different probiotic preparations on anti- Helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study显示文摘 | Filippo Cremonini Simona Di Caro Marcello Covino Alessandro Armuzzi Maurizio Gabrielli Luca Santarelli Enrico C Nista Giovanni Cammarota Giovanni Gasbarrini Antonio Gasbarrini | 2002 | The American Journal of Gastroenterology2002，，11： | 2 |
| 4 | Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agents显示文摘 | Alfredo Papa Carla Felice Manuela Marzo Gianluca Andrisani Alessandro Armuzzi Marcello Covino Giammarco Mocci Daniela Pugliese Italo De Vitis Antonio Gasbarrini Gian Lodovico Rapaccini Luisa Guidi | 2012 | Journal of Crohn’s and Colitis2012，，： | 2 |
| 5 | Lack of endoscopic visualization of intestinal villi with the “immersion technique” in overt atrophic celiac disease显示文摘 | Antonio Gasbarrini Veronica Ojetti Lucio Cuoco Giovanni Cammarota Alessio Migneco Alessandro Armuzzi Paolo Pola Giovanni Gasbarrini | 2003 | Gastrointestinal Endoscopy2003，，3： | 2 |
| 6 | Effect of LactobacillusGG supplementation on antibioticassociated gastrointestinal side effectsduring Helicobacter pylori eradication therapy:a pilot study显示文摘 | ARMUZZI A CREMONINI F OJETTI V | 2001 | Diges-tion2001，63，1： | 1 |
| 7 | OC.06.3 ADALIMUMAB IN ACTIVE ULCERATIVE COLITIS: A “REAL-LIFE” OBSERVATIONAL STUDY显示文摘 | A. Armuzzi L. Biancone M. Daperno A. Coli V. Annese S. Ardizzone P. Balestrieri F. Bossa F. Castiglione M. Cicala S. Danese R. D’Incà P. Dulbecco G. Feliciangeli W. Fries S. Genise P. Gionchetti S. Gozzi A. Kohn R. Lorenzetti M. Milla S. Onali A. Orlando | 2012 | Digestive and Liver Disease2012，，： | 1 |
| 8 | Extradigestive manifestations of Helicobacter pylori gastric infection显示文摘 | Gasbarrini A Franceschi F Armuzzi A | 1999 | Gut1999，，： | 1 |
| 9 | Gender affects 13C-ketoisocaproic acid breath test显示文摘 | Candelli M Armuzzi A | | 0，，06： | 1 |
| 10 | Anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab 显示文摘 | Armuzzi A Lionetti P Blandizzi C | 2014 | Int J Immunopathol Pharmacol2014，27，1： | 1 |
| 11 | Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with Crohn’s disease显示文摘 | Schinzari F Armuzzi A De Pascalis B | 2008 | Clinical Pharmacology Therapeutics2008，83，1： | 1 |
| 12 | A lyophilized and inactivated culture of Lactobacillus acido- philus increases Helicobocter pylori eradication rates 显示文摘 | CANDUCCI F ARMUZZI A CREMONINI F | 2000 | Aliment Pharmacol Ther2000，14，12： | 1 |
| 13 | The effect of oral administration of lactobacillus GG on antibiotic- associated gastrointestinal side effects during Helicobacter pylori eradication therapy显示文摘 | ARMUZZI A CREMONINI F BARTOLOZZI F | 2001 | Aliment Pharmacol Ther2001，15，2： | 1 |
| 14 | Anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab 显示文摘 | Armuzzi A Lionetti P Blandizzi C | 2014 | J Immunopathol Pharmacol2014，27，1： | 1 |
| 15 | The effect of o-ral administration of Lactobacillus GG on antibiotic-associated gastroin-testinal side-effects during Helicobacter pylori eradication therapy显示文摘 | ARMUZZI A CREMONINI F BARTOLOZZI F | 2001 | Aliment Pharmacol Ther2001，15，2： | 1 |
| 16 | Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with Crohn's disease显示文摘 | Schinzari F Armuzzi A De Pascalis B | 2008 | Clin Pharmacol Ther2008，83，1： | 1 |
| 17 | Update on the management of inflammatory bowel disease:specific role of adalimumab 显示文摘 | Guidi L Pugliese D Armuzzi A | 2011 | Clin Exp Gastroentero12011，4，： | 1 |
| 18 | The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side-effects during Heli-cobacter pylori eradication therapy显示文摘 | Armuzzi A Cremonini F Bartolozzi F | 2001 | Aliment PharmacolTher2001，15，2： | 1 |
| 19 | The molecular classification of the clinical manifestations of Crohn's disease显示文摘 | Ahmad T Armuzzi A Bunce M | 2002 | Gastroenterology2002，122，4： | 1 |
| 20 | Probiotics and Helicobacter pylori eradication显示文摘 | Canducci F Cremonini F Armuzzi A | 2002 | Dig Liver Dis2002，34，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员